Search

Your search keyword '"Behre, Hermann M"' showing total 687 results
Start Over Author "Behre, Hermann M"
687 results on '"Behre, Hermann M"'

152. Einleitung

Author

Nieschlag, Eberhard, primary, Bals-Pratsch, Monika, additional, Behre, Hermann M., additional, Knuth, Ulrich A., additional, Meschede, Dieter, additional, and Nieschlag, Susan, additional

Published
1993
Full Text
View/download PDF

154. Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME)

Author

Rosen, Raymond C, Wu, Frederick, Behre, Hermann M, Porst, Hartmut, Meuleman, Eric J H, Maggi, Mario, Romero-Otero, Javier, Martinez-Salamanca, Juan I, Jones, Thomas Hugh, Debruyne, Frans M J, Kurth, Karl-Heinz, Hackett, Geoff I, Quinton, Richard, Stroberg, Peter, Reisman, Yacov, Pescatori, Edoardo S, Morales, Antonio, Bassas, Lluis, Cruz, Natalio, Cunningham, Glenn R, Wheaton, Olivia A, RHYME Investigators, and Urology

Subjects
Gerontology, Adult, Male, medicine.medical_specialty, Hormone Replacement Therapy, Urology, Endocrinology, Diabetes and Metabolism, media_common.quotation_subject, Sexual Behavior, 030232 urology & nephrology, Testosterone Replacement Therapy, Cohort Studies, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Endocrinology, Quality of life (healthcare), Hormone replacement therapy (female-to-male), Phosphodiesterase Type 5 Inhibitors, Medicine, Humans, Testosterone, Longitudinal Studies, Prospective Studies, Registries, Young adult, Prospective cohort study, media_common, Sexual Function, Aged, 030219 obstetrics & reproductive medicine, business.industry, Rhyme, Hypogonadism, Penile Erection, Testosterone (patch), Middle Aged, Europe, Psychiatry and Mental health, Reproductive Medicine, Physical therapy, Quality of Life, business, Sexual function, Cohort study
Abstract

Background The benefits and risks of long-term testosterone administration have been a topic of much scientific and regulatory interest in recent years. Aim To assess long-term quality of life (QOL) and sexual function benefits of testosterone replacement therapy (TRT) prospectively in a diverse, multinational cohort of men with hypogonadism. Methods A multinational patient registry was used to assess long-term changes associated with TRT in middle-age and older men with hypogonadism. Comprehensive evaluations were conducted at 6, 12, 24, and 36 months after enrollment into the registry. Outcomes QOL and sexual function were evaluated by validated measures, including the Aging Males’ Symptom (AMS) Scale and the International Index of Erectile Function (IIEF). Results A total of 999 previously untreated men with hypogonadism were enrolled at 25 European centers, 750 of whom received TRT at at least one visit during the period of observation. Patients on TRT reported rapid and sustained improvements in QOL, with fewer sexual, psychological, and somatic symptoms. Modest improvements in QOL and sexual function, including erectile function, also were noted in RHYME patients not on TRT, although treated patients showed consistently greater benefit over time in all symptom domains compared with untreated patients. AMS total scores for patients on TRT were 32.8 (95% confidence interval = 31.3–34.4) compared with 36.6 (95% confidence interval = 34.8–38.5) for untreated patients (P Clinical Implications TRT-related benefits in QOL and sexual function are well maintained for up to 36 months after initiation of treatment. Strengths and Limitations The major strengths are the large, diverse patient population being treated in multidisciplinary clinical settings. The major limitation is the frequency of switching from one formulation to another. Conclusion Overall, we confirmed the broad and sustained benefits of TRT across major QOL dimensions, including sexual, somatic, and psychological health, which were sustained over 36 months in our treatment cohort.

Published
2017

156. Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment : Longitudinal Results From the Registry of Hypogonadism in Men (RHYME)

Author

Rosen, Raymond C., Wu, Frederick, Behre, Hermann M., Porst, Hartmut, Meuleman, Eric J. H., Maggi, Mario, Romero-Otero, Javier, Martinez-Salamanca, Juan I., Jones, Thomas Hugh, Debruyne, Frans M. J., Kurth, Karl-Heinz, Hackett, Geoff I., Quinton, Richard, Ströberg, Peter, Reisman, Yacov, Pescatori, Edoardo S., Morales, Antonio, Bassas, Lluis, Cruz, Natalio, Cunningham, Glenn R., Wheaton, Olivia A., Rosen, Raymond C., Wu, Frederick, Behre, Hermann M., Porst, Hartmut, Meuleman, Eric J. H., Maggi, Mario, Romero-Otero, Javier, Martinez-Salamanca, Juan I., Jones, Thomas Hugh, Debruyne, Frans M. J., Kurth, Karl-Heinz, Hackett, Geoff I., Quinton, Richard, Ströberg, Peter, Reisman, Yacov, Pescatori, Edoardo S., Morales, Antonio, Bassas, Lluis, Cruz, Natalio, Cunningham, Glenn R., and Wheaton, Olivia A.

Abstract

Background: The benefits and risks of long-term testosterone administration have been a topic of much scientific and regulatory interest in recent years. Aim: To assess long-term quality of life (QOL) and sexual function benefits of testosterone replacement therapy (TRT) prospectively in a diverse, multinational cohort of men with hypogonadism. Methods: A multinational patient registry was used to assess long-term changes associated with TRT in middle-age and older men with hypogonadism. Comprehensive evaluations were conducted at 6, 12, 24, and 36 months after enrollment into the registry. Outcomes: QOL and sexual function were evaluated by validated measures, including the Aging Males' Symptom (AMS) Scale and the International Index of Erectile Function (IIEF). Results: A total of 999 previously untreated men with hypogonadism were enrolled at 25 European centers, 750 of whom received TRT at at least one visit during the period of observation. Patients on TRT reported rapid and sustained improvements in QOL, with fewer sexual, psychological, and somatic symptoms. Modest improvements in QOL and sexual function, including erectile function, also were noted in RHYME patients not on TRT, although treated patients showed consistently greater benefit over time in all symptom domains compared with untreated patients. AMS total scores for patients on TRT were 32.8 (95% confidence interval = 31.3-34.4) compared with 36.6 (95% confidence interval = 34.8-38.5) for untreated patients (P < .001). Small but significant improvements in IIEF scores over time also were noted with TRT. Approximately 25% of treated and untreated men also used phosphodiesterase type 5 inhibitors, with notable differences in the frequency of phosphodiesterase type 5 inhibitor prescription use according to physician specialty and geographic site location. Clinical Implications: TRT-related benefits in QOL and sexual function are well maintained for up to 36 months after initiation of treatment. Stre

Published
2017
Full Text
View/download PDF

159. Treatment with human, recombinant FSH improves sperm DNA fragmentation in idiopathic infertile men depending on the FSH receptor polymorphism p.N680S: a pharmacogenetic study

Author

Simoni, Manuela, primary, Santi, Daniele, additional, Negri, Luciano, additional, Hoffmann, Ivan, additional, Muratori, Monica, additional, Baldi, Elisabetta, additional, Cambi, Marta, additional, Marcou, Marios, additional, Greither, Thomas, additional, Baraldi, Enrica, additional, Tagliavini, Simonetta, additional, Carra, Daniela, additional, Lombardo, Francesco, additional, Gandini, Loredana, additional, Pallotti, Francesco, additional, Krausz, Csilla, additional, Rastrelli, Giulia, additional, Ferlin, Alberto, additional, Menegazzo, Massimo, additional, Pignatti, Elisa, additional, Linari, Francesca, additional, Marino, Marco, additional, Benaglia, Renzo, additional, Levi-Setti, Paolo E., additional, and Behre, Hermann M., additional

Published
2016
Full Text
View/download PDF

160. Altered PIWI-LIKE 1 and PIWI-LIKE 2 mRNA expression in ejaculated spermatozoa of men with impaired sperm characteristics.

Author

Giebler, Maria, Greither, Thomas, Müller, Lisa, Mösinger, Carina, and Behre, Hermann M.

Abstract

In about half the cases of involuntary childlessness, a male infertility factor is involved. The PIWI-LIKE genes, a subclade of the Argonaute protein family, are involved in RNA silencing and transposon control in the germline. Knockout of murine Piwi-like 1 and 2 homologs results in complete infertility in males. The aim of this study was to analyze whether the mRNA expression of human PIWI-LIKE 1-4 genes is altered in ejaculated spermatozoa of men with impaired sperm characteristics. Ninety male participants were included in the study, among which 47 were with normozoospermia, 36 with impaired semen characteristics according to the World Health Organization (WHO) manual, 5th edition, and 7 with azoospermia serving as negative control for the PIWI-LIKE 1-4 mRNA expression in somatic cells in the ejaculate. PIWI-LIKE 1-4 mRNA expression in the ejaculated spermatozoa of the participants was measured by quantitative real-time PCR. In nonazoospermic men, PIWI-LIKE 1-4 mRNA was measurable in ejaculated spermatozoa in different proportions. PIWI-LIKE 1 (100.0%) and PIWI-LIKE 2 (49.4%) were more frequently expressed than PIWI-LIKE 3 (9.6%) and PIWI-LIKE 4 (15.7%). Furthermore, a decreased PIWI-LIKE 2 mRNA expression showed a significant correlation with a decreased sperm count ( P = 0.022) and an increased PIWI-LIKE 1 mRNA expression with a decreased progressive motility ( P = 0.048). PIWI-LIKE 1 and PIWI-LIKE 2 mRNA expression exhibited a significant association with impaired sperm characteristics and may be a useful candidate for the evaluation of the impact of PIWI-LIKE 1-4 mRNA expression on male infertility. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

162. The aging male: investigation, treatment and monitoring of late-onset hypogonadism in males

Author

Nieschlag, Eberhard, Swerdloff, Ronald, Behre, Hermann M., Gooren, L. J., Kaufman, J. M., Legros, J. J., Lunenfeld, Bruno, Morley, John E., Schulman, C., Wang, C., Weidner, W., and Wu, F. C. W.

Subjects
Hypogonadism -- Therapy, Hypogonadism, Testosterone
Abstract

Androgen deficiency in the aging male has become a topic of increasing interest and debate throughout the world. The demographics clearly demonstrate the increasing percentage of the population that is in the older age groups. The data also support the concept that testosterone falls progressively with age and that a significant percentage of men over the age of 60 years have serum testosterone levels that are below the lower limits of young adults (age 20-30 years) men. The principal questions raised by these observations are whether older hypogonadal men will benefit from testosterone treatment and what will be the risks associated with such intervention. The past decade has brought evidence of benefit of androgen treatment on multiple target organs of hypogonadal men and recent studies show short-term beneficial effects of testosterone in older men that are similar to those in younger men. Long-term data on the effects of testosterone treatment in the older population are limited and specific risk data on the prostate and cardiovascular systems are needed. Answers to key questions of functional benefits that may retard frailty of the elderly are not yet available. The recommendations described below were prepared for the International Society of Andrology (ISA) and the International Society for the Study of the Aging Male (ISSAM) following a panel discussion with active participation from the audience sponsored by the ISA on the topic at the 4th ISSAM Congress in Prague in February 2004., peer-reviewed

Published
2006

167. 10th Summit Meeting consensus : recommendations for regulatory approval for hormonal male contraception.

Author

Aaltonen, Pertti, Amory, John K, Anderson, Richard A, Behre, Hermann M, Bialy, Gabriel, Blithe, Diana, Bone, Wilhelm, Bremner, William J, Colvard, Doug, Cooper, Trevor G, Elliesen, Jörg, Gabelnick, Henry L, Gu, Yi-Qun, Handelsman, David J, Johansson, Elof A B, Kersemaekers, Wendy, Liu, Peter, MacKay, Trent, Matlin, Stephen, Mbizvo, Michael, McLachlan, Robert I, Meriggiola, Maria Cristina, Mletzko, Stephan, Mommers, Ellen, Muermans, Hilde, Nieschlag, Eberhard, Odlind, Viveca, Page, Stephanie T, Radlmaier, Albert, Sitruk-Ware, Regine, Swerdloff, Ronald, Wang, Christina, Wu, Frederick, Zitzmann, Michael, Aaltonen, Pertti, Amory, John K, Anderson, Richard A, Behre, Hermann M, Bialy, Gabriel, Blithe, Diana, Bone, Wilhelm, Bremner, William J, Colvard, Doug, Cooper, Trevor G, Elliesen, Jörg, Gabelnick, Henry L, Gu, Yi-Qun, Handelsman, David J, Johansson, Elof A B, Kersemaekers, Wendy, Liu, Peter, MacKay, Trent, Matlin, Stephen, Mbizvo, Michael, McLachlan, Robert I, Meriggiola, Maria Cristina, Mletzko, Stephan, Mommers, Ellen, Muermans, Hilde, Nieschlag, Eberhard, Odlind, Viveca, Page, Stephanie T, Radlmaier, Albert, Sitruk-Ware, Regine, Swerdloff, Ronald, Wang, Christina, Wu, Frederick, and Zitzmann, Michael

Published
2007
Full Text
View/download PDF

168. Testosterone treatment is not associated with increased risk of adverse cardiovascular events: results from the Registry of Hypogonadism in Men (RHYME).

Author

Maggi, Mario, Wu, Frederick C.W., Jones, Thomas H., Jackson, Graham, Behre, Hermann M., Hackett, Geoffrey, Martin‐Morales, Antonio, Balercia, Giancarlo, Dobs, Adrian S., Arver, Stefan T.E., Maggio, Marcello, Cunningham, Glenn R., Isidori, Andrea M., Quinton, Richard, Wheaton, Olivia A., Siami, Flora S., Rosen, Raymond C., Meuleman, E., Dohle, G., and Wu, F.

Subjects
ANDROGEN drugs, THERAPEUTIC use of testosterone, CARDIOVASCULAR diseases, COMPARATIVE studies, HYPOGONADISM, LONGITUDINAL method, RESEARCH methodology, MEDICAL cooperation, RESEARCH, EVALUATION research, ACQUISITION of data
Abstract

Aims: The aim of this study was to assess cardiovascular (CV) safety of testosterone replacement therapy (TRT) in a large, diverse cohort of European men with hypogonadism (HG).Methods: The Registry of Hypogonadism in Men (RHYME) was designed as a multi-national, longitudinal disease registry of men diagnosed with hypogonadism (HG) at 25 clinical sites in six European countries. Data collection included a complete medical history, physical examination, blood sampling and patient questionnaires at multiple study visits over 2-3 years. Independent adjudication was performed on all mortalities and CV outcomes.Results: Of 999 patients enrolled with clinically diagnosed HG, 750 (75%) initiated some form of TRT. Registry participants, including both treated and untreated patients, contributed 23 900 person-months (99.6% of the targeted) follow-up time. A total of 55 reported CV events occurred in 41 patients. Overall, five patients died of CV-related causes (3 on TRT, 2 untreated) and none of the deaths were adjudicated as treatment-related. The overall CV incidence rate was 1522 per 100 000 person-years. CV event rates for men receiving TRT were not statistically different from untreated men (P=.70). Regardless of treatment assignment, CV event rates were higher in older men and in those with increased CV risk factors or a prior history of CV events.Conclusions: Age and prior CV history, not TRT use, were predictors of new-onset CV events in this multi-national, prospective hypogonadism registry. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

172. World Health Organization reference values for human semen characteristics*‡

Author

Cooper, Trevor G., primary, Noonan, Elizabeth, additional, von Eckardstein, Sigrid, additional, Auger, Jacques, additional, Baker, H.W. Gordon, additional, Behre, Hermann M., additional, Haugen, Trine B., additional, Kruger, Thinus, additional, Wang, Christina, additional, Mbizvo, Michael T., additional, and Vogelsong, Kirsten M., additional

Published
2009
Full Text
View/download PDF

176. Proteomic analysis of acute promyelocytic leukemia: PML-RARα leads to decreased phosphorylation of OP18 at serine 63

Author

Zada, Abdul A. Peer, primary, Geletu, Mulu H., additional, Pulikkan, John A., additional, Müller-Tidow, Carsten, additional, Reddy, Venkateshwar A., additional, Christopeit, Maximilian, additional, Hiddemann, Wolfgang D., additional, Behre, Hermann M., additional, Tenen, Daniel G., additional, and Behre, Gerhard, additional

Published
2006
Full Text
View/download PDF

178. Significance of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone (FSH) receptor gene for the ovarian response to FSH: a pharmacogenetic approach to controlled ovarian hyperstimulation

Author

Behre, Hermann M., primary, Greb, Robert R., additional, Mempel, Andrea, additional, Sonntag, Barbara, additional, Kiesel, Ludwig, additional, Kaltwaer, Petra, additional, Seliger, Ewald, additional, Röpke, Friedrich, additional, Gromoll, Jörg, additional, Nieschlag, Eberhard, additional, and Simoni, Manuela, additional

Published
2005
Full Text
View/download PDF

180. BackMatter.

Author

Nieschlag, Eberhard, Schlatt, Stefan, Kliesch, Sabine, and Behre, Hermann M.

Published
2012

182. FrontMatter.

Author

Nieschlag, Eberhard, Schlatt, Stefan, Kliesch, Sabine, and Behre, Hermann M.

Published
2012

186. Hintergrund.

Author

Nieschlag, Eberhard, Schlatt, Stefan, Kliesch, Sabine, and Behre, Hermann M.

Published
2012
Full Text
View/download PDF

197. A 6-month observational study of energy, sexual desire, and body proportions in hypogonadal men treated with a testosterone 1% gel.

Author

Pexman-Fieth, Claire, Behre, Hermann M., Morales, Alvaro, Kan-Dobrosky, Natalia, and Miller, Michael G.

Subjects
*HYPOGONADISM, *AGING, *SEXUAL desire disorders, *MEN'S health, *MEDICAL statistics, *HEALTH outcome assessment, *THERAPEUTICS
Abstract

Aims and Methods: This was a 6-month, open label, multinational, observational study in hypogonadal men treated with daily titrated dose of 50, 75, or 100 mg 1% testosterone gel (AndroGel®) in community practice. Primary outcome was effect of treatment on hypogonadal symptoms and quality of life as assessed by Aging Males' Symptoms (AMS) scale. Secondary objectives included erectile dysfunction (International Index of Erectile Function [IIEF]), fatigue (Multidimensional Fatigue Inventory [MFI]), and surrogates for body composition (waist circumference, body mass index [BMI]). Results: Seven hundred and ninety-nine of the 1053 men enrolled had follow-up data at 6 months, 81.2% had ≥1 testosterone value in the normal range during the study. Substantial and significant improvements were observed in mean AMS score (−29%), IIEF score (+115.7%), and MFI scores (−21.5%). Further beneficial effects were significant decreases in mean BMI (−0.8 kg/m2) and waist circumference (−3.3 cm). Younger age quartiles showed greater improvements in AMS, MFI, BMI, and waist circumference than older quartiles. IIEF scores, however, did not differ significantly by age category. Conclusions: Substantial improvements in hypogonadal symptoms, quality of life, fatigue, erectile dysfunction, and libido/sexual desire were observed. Adverse drug reactions were experienced by 7.5% of the safety population over the 6-month study period. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results